Amit Munshi
CIK 1612551 · President and CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.52M
Companies
8
Total Filings
59
Lifetime Open-Market Net
-$27.27M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZURA | Director | 777,384 | $5.54 | $4.31M | $0 | 4 | 2026-06-22 |
| ARQT | Director | 9,799 | $28.42 | $278.5K | $0 | 2 | 2026-06-09 |
| IKT | Director | 403,176 | $2.31 | $931.3K | $500.1K | 5 | 2026-02-24 |
| Damora Therapeutics, Inc. (GLTO) Delisted | Director | 192 | $28.69 | $5.5K | $0 | 5 | 2025-06-20 |
| Zura Bio Ltd (ZURAW) Delisted | Director | 777,384 | $1.08 | $839.6K | $1000.0K | 3 | 2024-04-24 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | President and CEO | 114,647 | $99.99 | $11.46M | -$28.99M | 24 | 2022-03-11 |
| PULM | Director | — | $1.68 | — | $0 | 6 | 2021-02-01 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Chief Executive Officer | 301,841 | — | — | $221.8K | 10 | 2016-03-01 |
Recent Filings · Page 2 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-23 | IKT | Mixed | +365,000 | $500.1K | EDGAR |
| 2024-09-06 | ZURA | Grant (A) | +159,744 | $500.0K | EDGAR |
| 2024-06-21 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-24 | Zura Bio Ltd (ZURAW) Delisted | Buy (P) | +159,744 | $500.0K | EDGAR |
| 2023-06-15 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | Zura Bio Ltd (ZURAW) Delisted | Buy (P) | +117,647 | $500.0K | EDGAR |
| 2023-06-02 | Zura Bio Ltd (ZURAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-15 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-11 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Mixed | −125,397 | -$1.03M | EDGAR |
| 2022-01-05 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | +85,847 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.